Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Metabolic Impairment in Coronary Artery Disease: Elevated Serum Acylcarnitines Under the Spotlights
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 4643254
Author(s) Gander, Joséphine; Carrard, Justin; Gallart-Ayala, Hector; Borreggine, Rébecca; Teav, Tony; Infanger, Denis; Colledge, Flora; Streese, Lukas; Wagner, Jonathan; Klenk, Christopher; Nève, Gilles; Knaier, Raphael; Hanssen, Henner; Schmidt-Trucksäss, Arno; Ivanisevic, Julijana
Author(s) at UniBasel Infanger, Denis
Schmidt-Trucksäss, Arno
Hanssen, Henner
Colledge, Flora
Knaier, Raphael
Klenk, Christopher
Nève, Gilles
Carrard, Justin
Gander, Joséphine
Wagner, Jonathan
Streese, Lukas
Year 2021
Title Metabolic Impairment in Coronary Artery Disease: Elevated Serum Acylcarnitines Under the Spotlights
Journal Frontiers in Cardiovascular Medicine
Volume 8
Pages / Article-Number 792350
Keywords acylcarnitine; branched-chain amino acids; carnitine; coronary artery disease; fatty acid oxidation (FAO); metabolomics; mitochondria
Abstract Coronary artery disease (CAD) remains the leading cause of death worldwide. Expanding patients' metabolic phenotyping beyond clinical chemistry investigations could lead to earlier recognition of disease onset and better prevention strategies. Additionally, metabolic phenotyping, at the molecular species level, contributes to unravel the roles of metabolites in disease development. In this cross-sectional study, we investigated clinically healthy individuals (; n; = 116, 65% male, 70.8 ± 8.7 years) and patients with CAD (; n; = 54, 91% male, 67.0 ± 11.5 years) of the COmPLETE study. We applied a high-coverage quantitative liquid chromatography-mass spectrometry approach to acquire a comprehensive profile of serum acylcarnitines, free carnitine and branched-chain amino acids (BCAAs), as markers of mitochondrial health and energy homeostasis. Multivariable linear regression analyses, adjusted for confounders, were conducted to assess associations between metabolites and CAD phenotype. In total, 20 short-, medium- and long-chain acylcarnitine species, along with L-carnitine, valine and isoleucine were found to be significantly (adjusted; p; ≤ 0.05) and positively associated with CAD. For 17 acylcarnitine species, associations became stronger as the number of affected coronary arteries increased. This implies that circulating acylcarnitine levels reflect CAD severity and might play a role in future patients' stratification strategies. Altogether, CAD is characterized by elevated serum acylcarnitine and BCAA levels, which indicates mitochondrial imbalance between fatty acid and glucose oxidation.
Publisher Frontiers Media
ISSN/ISBN 2297-055X
edoc-URL https://edoc.unibas.ch/88267/
Full Text on edoc Available
Digital Object Identifier DOI 10.3389/fcvm.2021.792350
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/34977199
ISI-Number WOS:000738759600001
Document type (ISI) Journal Article
 
   

MCSS v5.8 PRO. 0.374 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
23/06/2024